Cancer Risk in Type 2 Diabetes Widens in 25-Year Study

Cancer Incidence Gap Widens for People with Type 2 Diabetes

Adults with type 2 diabetes (T2D) face a higher risk of developing cancer than peers without diabetes, with the difference growing over recent decades. Nationwide Danish registry data presented at the European Association for the Study of Diabetes (EASD) annual meeting tracked entire adult populations from 1996 to 2022. During 2010 to 2022, overall cancer incidence was 12 percent higher in men and 22 percent higher in women diagnosed with T2D compared to those without the condition.

The disparity expanded from the earlier 1996 to 2009 observation window. In that earlier period, cancer rates were 9 percent higher in men and 15 percent higher in women with T2D. Over the full 27-year study period, researchers identified 75,540 first cancers in individuals with T2D and 635,323 in those without diabetes.

Obesity-Related Cancers Drive the Expanding Gap

The increase in cancer rates among adults with type 2 diabetes is largely driven by obesity-related malignancies. Between 2010 and 2022, incidence rates for obesity-related cancers were 45 percent higher in men and 30 percent higher in women with T2D than in those without diabetes. These figures show a clear rise from the 1996 to 2009 period, when differences were 34 percent for men and 23 percent for women.

Specific tumor types showed distinct patterns across sexes. Colorectal cancer incidence was 17 percent higher in men and 14 percent higher in women with T2D during the 2010 to 2022 window. Postmenopausal breast cancer incidence was 8 percent higher among women with T2D during the same timeframe.

Non-Obesity Cancer Rates Vary by Tumor Type

Cancer patterns outside the obesity-related category showed divergent trends across different organs. Men with T2D had a 19 percent lower incidence of prostate cancer between 2010 and 2022 than men without diabetes. Researchers also observed distinct shifts in lung cancer diagnoses over time.

Lung cancer incidence between 2010 and 2022 was 23 percent higher in men and 25 percent higher in women with T2D compared to those without the condition. For women, this marked a reversal from the 1996 to 2009 window, when lung cancer incidence was 12 percent lower in women with T2D.

Proposed Mechanisms and Diabetes Care Priorities

Biological drivers linking metabolic dysfunction to malignancy include chronic hyperinsulinemia and persistent tissue inflammation. Sustained exposure to elevated blood sugar levels, elevated insulin levels, and insulin resistance may promote tumor growth. In Denmark and other high-income countries, cancer has emerged as the leading cause of death among people living with T2D.

Lead researcher Dr. Tinne Laurberg from Steno Diabetes Center Aarhus emphasized that cancer prevention must become a core component of long-term diabetes care. While cardiovascular and kidney protections remain standard priorities, comprehensive diabetes management also requires systematic engagement with cancer screening programs.

• Encourage regular participation in established screening programs for colorectal cancer and postmenopausal breast cancer.
• Recognize cancer as a primary long-term complication alongside cardiovascular disease and kidney impairment.
• Discuss personal screening schedules and symptom awareness with a primary healthcare clinician.

Observational Registry Design and Context

The findings reflect an observational analysis using nationwide health registries in Denmark rather than a randomized intervention trial. Researchers followed Danish residents aged 18 and older starting in 1996, classifying participants as having T2D only after a formal diagnosis was recorded. Follow-up concluded upon cancer diagnosis, emigration, death, or the study cutoff on December 31, 2022.

Observational registry studies capture broad population-level trends but cannot independently establish direct causation between metabolic markers and specific tumor mutations. Differences in medical surveillance, detection rates, and unmeasured lifestyle factors may influence recorded incidence gaps across decades. Individuals managing diabetes should talk to their clinician about age-appropriate cancer screenings.